ArticleJournal of clinical microbiology2022
Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).
Article in Journal of clinical microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Pooled it
- Outcomes byAntimicrobial agents and chemotherapy · 2024Trial
- WaaL-WaaP receptor cross-talk drives phage-induced collateral sensitivity to colistin in Salmonella Pullorum.Veterinary research · 2026Article
- Activity of Isavuconazole and Comparator Agents Against Pediatric Isolates From Invasive Fungal Infections.Journal of the Pediatric Infectious Diseases Society · 2026Article
- Synergistic disinfection by phage PLY101 and 1.3-dibromo-5.5-dimethylhydantoin (DBDMH) against resistant Proteus mirabilis.BMC microbiology · 2026Article
- Genomic Insights ofOpen forum infectious diseases · 2026Review
- Large-scale virtual screening of 17,967 IMPPAT phytochemicals identifies multiple CDR1 binders and reveals Apigenin-7-O-glucuronide as a putative CDR1-GSC1 dual-target lead againstFrontiers in cellular and infection microbiology · 2026Article
- Triazole-functionalized compounds as promising antifungal agents: Synthesis, biological evaluation, and mechanistic insights.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Identification and antifungal susceptibility patterns of reference yeast strains to novel and conventional agents: a comparative study using CLSI, EUCAST and Sensititre YeastOne methods.JAC-antimicrobial resistance · 2025Article
- Activity of Rezafungin Against Echinocandin Non-wild typeOpen forum infectious diseases · 2025Article
- An 11-Year retrospective analysis of candidiasis epidemiology, risk factors, and antifungal susceptibility in a tertiary care hospital in China.Scientific reports · 2025Article
- Anidulafungin is a useful surrogate marker for predictingJournal of clinical microbiology · 2025Article
- Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.Clinical microbiology reviews · 2024Review
- In Vitro Activitiy of Rezafungin in Comparison with Anidulafungin and Caspofungin against Invasive Fungal Isolates (2017 to 2022) in China.Journal of fungi (Basel, Switzerland) · 2024Article
- Invasive fungal infections and oomycoses in cats 2. Antifungal therapy.Journal of feline medicine and surgery · 2024Review
- Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis.Antimicrobial agents and chemotherapy · 2023Article
- Study of Combined Effect of Bacteriophage vB3530 and Chlorhexidine on the Inactivation of Pseudomonas aeruginosa.BMC microbiology · 2023Article
- Rezafungin: First Approval.Drugs · 2023Review
- Antifungal resistance, combinations and pipeline: oh my!Drugs in context · 2023Review
- Necrotizing gingival infection due toTherapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Rezafungin is a new echinocandin under development for the treatment of candidemia and invasive candidiasis. CLSI recently approved provisional susceptible-only breakpoints and epidemiological cutoff values for
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.